View Press Releases

Medidata and PPD Partner to Offer New Approach to Risk-Based Monitoring

November 7, 2014
Joint Effort to Enable Faster, Safer and Smarter Clinical Trial Reviews for Life Science Industry

NEW YORK, NY - Nov 4, 2014 - Medidata (NASDAQ: MDSO), a leading global provider of cloud-based solutions for clinical research in life sciences, and Pharmaceutical Product Development, LLC (PPD), a global contract research organization (CRO), today announced they are expanding their partnership to provide the life science industry with a more comprehensive approach to risk-based monitoring (RBM)-aimed at conducting drug development more intelligently, more quickly and more cost-effectively.

 

“We’re very excited about extending our partnership with a world-class CRO like PPD,” said Glen de Vries, Medidata’s president. “PPD and Medidata share a common vision of transforming drug development through the power of technology and the intelligent use of data for the benefit of our customers.”

 

This effort combines processes to increase data sampling and tracking of source document verification (SDV) through Medidata TSDV (targeted source document verification) with site health assessments and risk evaluation through PPD’s adaptive and intelligent monitoring. This new endeavor will afford clinical research associates increased scrutiny of targeted endpoints that pose the greatest areas of risk in studies. Through this new arrangement, the companies will track specific SDV requirements and compliance directly within electronic data capture systems and will have greater opportunity to focus remote monitoring on targeted critical data points.

 

In today’s clinical trials, site monitoring costs can account for up to 30 percent of a trial’s budget. By combining PPD’s clinical trial expertise in alternative monitoring approaches with Medidata’s innovative clinical trial technology, they can jointly offer faster, less-costly data quality reviews, without compromising the core focus on patient safety and compliance with industry regulatory requirements.

 

“Medidata’s TSDV solution closely complements PPD’s adaptive and intelligent approach to risk-based monitoring,” said Lori Eberhardt, PPD’s vice president of remote site management and remote monitoring. “PPD adapts SDV sampling and clinical monitoring visit schedules based on site health recorded in Preclarus™-our real-time data and analysis solution for consolidating and standardizing data from multiple sources. PPD also offers clients its standard RBM solutions, such as adaptive and intelligent monitoring, that leverage the technological advances of Preclarus to adjust monitoring schedules on a site-by-site basis as a result of ongoing risk assessments. Combining Preclarus with Medidata TSDV offers an opportunity for us to increase the breadth of data used to develop these schedules and plans. Partnering with Medidata to enhance our RBM strategy is another example of how PPD is taking advantage of our industry-leading people, technology and processes to offer more effective and efficient adaptive and intelligent monitoring plans.”

 

Connect with Medidata:

 

About PPD

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. PPD’s clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.

 

About Medidata Solutions

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. 

 

###

 

Investor Contact:

Hulus Alpay

Medidata Solutions

212.419.1025

halpay@mdsol.com

 

Media Contact -Americas:

Nicole Pariser

Medidata Solutions

212.659.1069

npariser@mdsol.com

 

Media Contact - EMEA:

Jayson Otke

Medidata Solutions

+44(0) 7930 104480

jotke@mdsol.com